iβeCa Therapeutics, Inc.

iβeCa Therapeutics to focus on discovery and development activities needed to identify candidates for human clinical testing. from the in licensed proprietary compounds from NYU School of Medicine that target the Wnt signalling pathway.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Website
Founded2016
Disease Focus
Development Stage
STOCK CODENon Listed
Address
United States
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]